Blog

Transforming CRISPR Gene Editing Workflows: High-Throughput Edit Screening with PACE Genotyping

Genome editing, especially with CRISPR/Cas systems, is revolutionizing genetic research. Its applications range from enhancing crop traits in agriculture to advancing cell line development in life sciences. However, one major challenge remains: efficiently identifying successful edits in large populations.

Enter PACE® (PCR Allele Competitive Extension) genotyping—a game-changing tool that addresses these screening challenges. In our latest application note, High-Throughput Screening of Gene Edits Using PACE Allele-Specific Genotyping for Agriculture and Life Sciences, we show how PACE reshapes genome editing workflows by providing a faster, cost-effective, and scalable alternative to traditional sequencing.

The Landscape of Genome Editing

CRISPR/Cas systems allow for a range of genetic modifications:

• Single base-pair changes
• Frameshifts
• Gene knockouts
• Small and large insertions or deletions (InDels)

These edits are achieved via Non-Homologous End Joining (NHEJ) or Homology-Directed Repair (HDR) mechanisms. While these tools promise unparalleled precision, screening for successful edits remains a bottleneck, often relying on Sanger or Next-Generation sequencing.

However, large-scale sequencing comes with significant drawbacks:

• Cost: High expenses for large populations
• Sample Purity Requirements: Demanding high-purity DNA extractions
• Data Overload: Large datasets necessitating advanced analysis

PACE genotyping offers a streamlined, PCR-based alternative, eliminating these hurdles with its high-throughput, allele-specific detection capabilities.

PACE Genotyping: A Game-Changer for CRISPR-Based Gene Editing

PACE genotyping simplifies and accelerates genome editing workflows with key advantages:

1. Broad Applicability
Applicable across plants, animals, tissue cultures, protoplasts, seeds, and more, PACE fits seamlessly into diverse research environments.

2. Efficiency

  • Detects SNPs, knockouts, and various insertions/deletions.
  • Employs simple unlabeled primers for real-time or endpoint analysis.

3. Cost-Effectiveness

  • Operates with minimal DNA input, working efficiently even with crude lysates.
  • Reduces reliance on expensive sequencing by pre-screening populations.

4. High Accuracy
Allele-specific primers ensure precise differentiation between wild-type and edited sequences.

5. Versatility

  • Detects zygosity and tracks genetic changes through breeding cycles.
  • Functions in both DNA-mediated and DNA-free editing processes.

6. User-Friendly Workflow

  • Combines target amplification and fluorescence detection in one step on standard qPCR machines.
  • Tailored workflows ensure smooth adoption for researchers of all expertise levels.

Spotlight: CRISPR Applications in Plant Breeding

CRISPR/Cas systems have become indispensable in plant breeding, facilitating the development of crops with enhanced traits. PACE genotyping supports this by:

  • Optimizing Genome Editing: Detecting edits early to refine protocols.
  • Bulk Screening: Testing seed populations for trait purity.
  • Regulatory Dossiers: Providing robust data for approvals.
  • Market Monitoring: Tracking edits in commercial products.

Whether detecting single-nucleotide changes (SDN1) or large rearrangements (SDN3), PACE is a versatile and reliable tool.

Key Benefits of PACE for CRISPR Research

PACE genotyping is a valuable tool for researchers working with CRISPR-based genome editing. Its ability to detect SNPs, insertions, and deletions early in the process reduces costs and accelerates project timelines. With minimal DNA input requirements, compatibility with crude lysates, and even with multiplex options, PACE offers a streamlined solution for high-throughput screening in CRISPR workflows.

Case Study: Cost-Efficiency in Action with CoverCress Inc.

CoverCress Inc. (CCI) is revolutionizing agriculture by domestically modifying pennycress into a third rotational crop for U.S. corn/soybean systems. To do this, CCI employs CRISPR to edit 30–50 germplasms annually. However, genotyping bottlenecks posed significant hurdles, particularly with the high costs and delays associated with Sanger sequencing.

By partnering with 3CR Bioscience to integrate PACE genotyping, CCI achieved:

  • 70–80% Cost Reductions: Streamlining edit conversion processes.
  • Scalability: Supporting larger volumes of edited lines.
  • Multiplexing Capabilities: Screening multiple unique edits simultaneously.

PACE assays have become indispensable in CCI’s marker-assisted selection (MAS) program, enabling efficient marker selection with edited germplasm across diverse crops.

Transform Your CRISPR Genome Editing Workflow

Ready to enhance your CRISPR genome editing workflow? Download our application note and discover how PACE genotyping can streamline your research. Let’s shape the future of CRISPR technology—together.

Discover More About PACE Genotyping

CRIPSR workflows

MORE POSTS

CRIPSR workflows
Transforming CRISPR Gene Editing Workflows: High-Throughput Edit Screening with PACE Genotyping
3CR Bioscience’s Cutting-Edge SNP Genotyping Instrumentation: High-Throughput Automation Powered by PACE®
SNP Genotyping and High-Resolution Mapping of a Novel Hybrid Susceptibility Locus in Barley Using PACE® Genotyping Technology
[fibosearch]
Name(Required)
This field is for validation purposes and should be left unchanged.

Contact us

MEET OUR TEAM

Steve Asquith Managing Director
Steve began his career in the Genetics Division of GlaxoSmithKline, as part of the team establishing GSK’s high-throughput core genotyping laboratory. Steve joined KBioscience when it was first founded in 2002 and was a key driver in taking the company from a small start-up to a multi-national service laboratory, quickly growing the company’s revenue to over $7.5M p.a. Following the acquisition of Kbioscience by LGC in 2011, Steve was appointed Global Director of Operations for LGC Genomics, responsible for over 100 staff in Europe and N. America, successfully elevating the genotyping products and service business. Steve held a crucial leadership role until he left in 2016. In 2017 Steve joined forces with John Holme to create 3CR Bioscience, a new company with a mission to deliver outstanding, customer-focused genotyping products with innovation and affordability at its core.
Dr. John Holme Technical Director
John joined KBioscience shortly after it was founded, in 2003, and became Head of Technical Development, building the company’s genotyping and DNA extraction product portfolio and service delivery until 2011 when it was acquired by LGC. Post-acquisition, John was appointed Head of Technical Group for LGC Genomics, in charge of all Research & Development and Technical Support activities for the company. In this role John continued to build on the high-quality products and services provided to the companies growing customer base. During the 19 years John has worked in commercial R&D, he has co-invented numerous highly successful products including PACE®, ProbeSure, KASPâ„¢, KlearKall, KlearGene, KlearAmp and KlearTaqâ„¢, creating breakthrough offerings in genotyping and extraction and generating huge revenues for the companies he has worked in. In 2017, he joined forces with Steve Asquith and started 3CR Bioscience. John is dedicated to developing outstanding, innovative genotyping products and providing the very best technical support to customers globally.
Dr. Nisha JainOperations Director
Nisha has been innovating since the start of her career at Geneform Technologies developing Iso-thermal Genotyping Technologies. Nisha joined KBioscience in 2008, as Senior R&D Scientist and key account Technical Support Scientist, developing KASP and Klearkall performance and coinventing two further versions of KASP. Nisha has more than 15 years’ experience working in molecular biology and genotyping technologies, with extensive experience in the areas of R&D, Quality Assurance and Customer Technical Support. She has technically assisted many giants of the industry with their protocol development and troubleshooting and continues to deliver high-quality support and guidance. In 2018, Nisha joined 3CR Bioscience as Operations Director where she continues to develop PACE and ProbeSure for an increasing range of applications, and to grow 3CR Bioscience’s new product pipeline. Nisha is dedicated to developing outstanding, innovative genotyping products and providing the very best technical support to customers globally.
Nazma Saffin General Manager
For 20 years Nazma Saffin has worked and gained extensive expertise within the genotyping sector. Working at Kbioscience and then LGC, she has held operational leadership posts responsible for manufacturing and laboratory services. With experience of ISO 9001 implementation, production scale up and LEAN operations, Nazma has successfully led highly profitable production departments. Joining 3CR Bioscience in 2022, Nazma is committed to delivering operational excellence.
Jon Curtis Non-Executive Chair
After 8 years in The Royal Air Force, Jon moved to the Imperial Cancer Research Fund where he pioneered the use of ultra high-throughput genomic automation, capable of 46,000 PCRs per hour. In the 1990’s Jon joined GlaxoSmithKline, implementing a high-throughput genomics platform into their drug discovery pipeline. Whilst there he also developed acoustic mixing into compound management, becoming the gold standard across pharma. Jon developed the world’s first commercially viable 1536-well PCR plates, automated thermal & laser plate-sealer, plus automated liquid-handling & tip washing tools to reduce waste and costs. In 2002 Jon co-founded KBioscience with Phil Robinson, utilising ultra high-throughput PCR instrumentation & a suite of automation tools to create the company’s SNPline robotic platform, with a capacity of 250,000 PCRs/day. The business was underpinned by their ground-breaking patented genotyping chemistry, KASP™, which has over 10,000 scientific papers to date. In November 2022 Jon joined 3CR Bioscience acting as an advisor bringing his commercial and scientific experience to the company.